Connor, Clark & Lunn Investment Management Ltd. Bluebird Bio, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 05, 2022	BUY	$2.94 - $5.23 $124,958 - $222,290	42,503 Added 81.16%	94,875 $393,000
Q1 2022 May 12, 2022	BUY	$4.07 - $10.6 $213,154 - $555,143	52,372 New	52,372 $254,000
Q4 2021 Feb 10, 2022	SELL	$8.96 - $16.31 $679,974 - $1.24 Million	-75,890 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$11.24 - $21.0 $115,131 - $215,103	-10,243 Reduced 11.89%	75,890 $1.45 Million
Q2 2021 Aug 12, 2021	BUY	$18.04 - $22.09 $1.19 Million - $1.46 Million	66,090 Added 329.74%	86,133 $2.76 Million
Q1 2021 May 13, 2021	BUY	$16.59 - $33.89 $332,513 - $679,257	20,043 New	20,043 $604,000
Q2 2020 Aug 13, 2020	SELL	$27.12 - $45.97 $432,564 - $733,221	-15,950 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$26.16 - $63.5 $319,806 - $776,287	12,225 Added 328.19%	15,950 $474,000
Q4 2019 Feb 12, 2020	BUY	$46.96 - $61.67 $174,926 - $229,720	3,725 New	3,725 $327,000

Others Institutions Holding BLUE

# of Institutions

151

Shares Held

63.4M

Call Options Held

264K

Put Options Held

428K

Black Rock Inc. New York, NY

15.4M
Shares

$5.71 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

10.5M
Shares

$3.88 Million
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

4.68M
Shares

$1.73 Million
0.0% of portfolio
Pictet Asset Management Sa Geneva 73, V8

4.67M
Shares

$1.73 Million
0.02% of portfolio
State Street Corp Boston, MA

3.84M
Shares

$1.42 Million
0.0% of portfolio

View Full List

About bluebird bio, Inc.

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

More about BLUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account